Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to 35% from the current price [4][7]. Core Insights - The company reported a revenue of RMB 13.82 billion for 2025, representing a year-over-year increase of 34.2%. The net profit attributable to shareholders was RMB 1.89 billion, up 49.6% year-over-year, with a non-recurring net profit of RMB 1.79 billion, reflecting a 77.0% increase [4]. - The domestic market continues to benefit from the implementation of medical equipment upgrade policies, while the overseas market expansion is strengthening. The demand for high-end medical imaging and radiation therapy equipment is expected to grow significantly due to ongoing policy support [4]. - The company is projected to achieve net profits of RMB 2.29 billion, RMB 2.71 billion, and RMB 3.17 billion for the years 2025 to 2028, with year-over-year growth rates of 21.3%, 18.2%, and 17.3% respectively [4][6]. Company Overview - The company operates primarily in the medical imaging and radiation therapy equipment sector, with 87.8% of its revenue coming from sales of these devices. Maintenance services contribute 9.5%, while software business accounts for 1.1% [4]. - The current market capitalization of the company is approximately RMB 105.04 billion, with a price-to-earnings ratio projected to decrease from 46 times in 2025 to 33 times in 2028 [4][6]. Financial Projections - The company is expected to generate revenues of RMB 12.98 billion in 2025, RMB 15.53 billion in 2026, and RMB 18.26 billion in 2027, with corresponding net profits of RMB 1.89 billion, RMB 2.29 billion, and RMB 2.71 billion [6][9]. - The earnings per share (EPS) are projected to be RMB 2.29 in 2025, RMB 2.78 in 2026, and RMB 3.28 in 2027, indicating a positive growth trajectory [6][9].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside of 15% to 35% from the current price [4]. Core Insights - The company reported a revenue of RMB 13.82 billion for 2025, representing a year-over-year increase of 34.2%. The net profit attributable to shareholders was RMB 1.89 billion, up 49.6% year-over-year, with a non-recurring net profit of RMB 1.79 billion, reflecting a 77.0% increase [4]. - The domestic market continues to benefit from the implementation of medical equipment upgrade policies, while the overseas market expansion is strengthening. The demand for high-end medical imaging and radiation therapy equipment is expected to grow significantly due to ongoing policy support [4]. - The company is projected to achieve net profits of RMB 2.29 billion, RMB 2.71 billion, and RMB 3.17 billion for the years 2025 to 2028, with year-over-year growth rates of 21.3%, 18.2%, and 17.3% respectively [4][6]. Summary by Sections Company Overview - The company operates primarily in the medical and biological industry, focusing on medical imaging diagnostic equipment (87.8% of sales), maintenance services (9.5%), and software business (1.1%) [1]. Financial Performance - The company achieved a quarterly revenue of RMB 4.96 billion in Q4 2025, marking a 48.3% year-over-year increase, with a net profit of approximately RMB 770 million, up 29.9% year-over-year [4]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are RMB 2.8, RMB 3.3, and RMB 3.9 respectively, with corresponding price-to-earnings (P/E) ratios of 46x, 39x, and 33x [4][6]. Market Dynamics - The report highlights that the Chinese market is entering a phase of normalized and specialized implementation of large-scale medical equipment upgrades, leading to a significant recovery in industry scale compared to the previous year [4]. - The company is enhancing its global market presence, with rapid growth in key regions such as Europe, North America, and emerging markets, thereby increasing its brand influence and customer penetration [4].